ResMed Inc (RMD)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE
Market Cap: $33.69B
Last updated: Nov 17, 2026 at 11:06 AM ET
ResMed Inc (RMD) P/E Ratio & Valuation History
ResMed (RMD) trades at 20.7x trailing earnings and 5.9x sales. Its P/E of 20.7x is below its 5-year median of 27.8x. Its forward P/E is 20.0x. The median P/E across 11 similar companies is 21.2x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 3.5% higher over the next year. Its free cash flow yield is 4.7%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 20.7x |
| Forward P/E | 20.0x |
| Price to sales | 5.9x |
| Price to book | 5.7x |
| EV/EBITDA | 15.3x |
| Price to FCF | 21.2x |
| EV/FCF | 20.8x |
| PEG | 1.3 |
| FCF yield | 4.7% |
Historical Medians
Against its 10-year medians, its P/E is 31.0% below 30.0x, its P/S is 15.7% below 7.0x and its P/B is 23.0% below 7.4x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 20.7x | 27.8x | 30.0x |
| P/S | 5.9x | 7.2x | 7.0x |
| P/B | 5.7x | 6.5x | 7.4x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 22.4x in 2016 to 46.3x in 2021.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $240.87 | 23.4x | 6.5x | 5.6x |
| 2024 | $228.69 | 25.9x | 6.8x | 6.4x |
| 2023 | $172.02 | 25.3x | 5.6x | 5.6x |
| 2022 | $208.13 | 34.8x | 8.1x | 8.2x |
| 2021 | $260.48 | 46.3x | 11.0x | 12.1x |
| 2020 | $212.56 | 40.1x | 10.0x | 10.8x |
| 2019 | $154.97 | 38.9x | 8.0x | 9.9x |
| 2018 | $113.87 | 30.9x | 6.6x | 8.3x |
| 2017 | $84.69 | 27.0x | 5.5x | 6.0x |
| 2016 | $62.05 | 22.4x | 4.4x | 5.1x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About RMD
What is RMD's forward P/E ratio?
ResMed has a forward P/E ratio of 20.0x.
Is RMD stock overvalued?
GNG's valuation label for RMD is Undervalued. Its P/E of 20.7x compares with a median of 21.2x across 11 similar companies.
What is RMD's price to sales ratio?
ResMed has a price to sales ratio of 5.9x.
What is ResMed's average P/E ratio over 5 years?
ResMed's median P/E over the last 5 years is 27.8x, from 60 month-end values through Oct 2026.
What is RMD's PEG ratio?
ResMed has a PEG ratio of 1.3.
RMD pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors